Generic and specialty drug manufacturer Amneal Pharmaceuticals is offering refunds for 340B overcharges on an 18-page-long list of products for purchases between Q3 2019 and Q3 2022.
The U.S. Health Resources and Services Administration posted New Jersey-based Amneal’s notice to 340B covered entities on the Office of Pharmacy Affairs website yesterday. The company said its revised 340B ceiling prices are due to revised pricing data submitted to the Centers for Medicare & Medicaid Services.
“Amneal has determined the credit amount owed to each affected covered entity,” the notice said. “Amneal will be working through Apexus, the HRSA 340B Prime Vendor, to issue refunds for each affected Covered Entity. Refunds will be issued either to a Covered Entity’s validated wholesaler pharmacy account when one can be identified, or a check will be issued to Covered Entities whose wholesaler account cannot be identified.”
The notice includes contact information for covered entities that think they are owed a refund but that are not contacted by Apexus by July 1, 2023.